www.latimes.com

www.latimes.com
Share

www.latimes.com

 •  January 26

Tobacco giant Philip Morris had mixed success on Thursday in its bid to sell a federal advisory panel on the wisdom of offering U.S. smokers a potentially safer alternative to cigarettes. After two days of meetings outside of Washington, D.C., the Food and Drug Administration's Tobacco Products Scientific Advisory Committee offered a lukewarm...

www.latimes.com

 •  December 20, 2017

West Virginia Attorney General Patrick Morrisey says the state will receive more than $153,000 in a national settlement with a prescription drug manufacturer. Morrisey says in a news release that every state and the District of Columbia are participating in the $13.5 million settlement with Boehringer Ingelheim Pharmaceuticals Inc. The settlement...

www.latimes.com

 •  December 19, 2017

Of all the proposals in the GOP tax plan, none may be more important to families like Jay and Amy Granzow than an obscure provision on “orphan” drug research.The Granzows, who live in Manhattan Beach, fear that the final tax bill will end up killing or drastically cutting a three-decade-old tax credit for companies developing therapies for...

www.latimes.com

 •  December 6, 2017

Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. But a new study finds that programs already in place were routinely shortening the drug development process by close to a...

www.latimes.com

 •  November 29, 2017

Alex Azar, a former pharmaceutical executive tapped by President Trump to be Health and Human Services secretary, told senators Wednesday that making prescription drugs more affordable would be one of his top priorities.“Drug prices are too high,” Azar told the Senate health committee, pledging to look at ways to increase competition and stop...

www.latimes.com

 •  October 24, 2017

With high drug prices still in the political crosshairs on Capitol Hill, pharmaceutical industry bosses are at pains to explain why a cure for hepatitis-C has to cost a budget-busting $1,000 per pill, or a promising cancer treatment should carry a list price of $373,000. That duty most recently fell to John C. Martin, the executive chairman of...

www.latimes.com

 •  October 22, 2017

After scientists at UCLA created a breakthrough treatment for prostate cancer, it generated more than half a billion dollars for the university. But deals struck with drugmakers also obligated university officials to help pursue patent protection for the drug around the world. Now, consumer activists claim that UCLA’s efforts are propping up the...

www.latimes.com

 •  October 9, 2017

Pharmaceutical companies have so much power over their customers, it’s practically an abusive relationship. Maybe that’s why consumer advocates are heralding what might otherwise seem like a minor legislative win over Big Pharma. SB 17, which Gov. Jerry Brown signed Monday morning, would not stop drug companies from making a brand new drug costlier...

www.latimes.com

 •  September 22, 2017

Seeking to prevent superbug outbreaks, federal health officials said they have approved the first gastrointestinal medical scope with a disposable cap for use in the U.S. The Food and Drug Administration said that the design of the new duodenoscope by Japanese device maker Pentax should make it easier to remove dangerous bacteria that can become...

www.latimes.com

 •  August 31, 2017

In a step that heralds a new era in cancer treatment, the U.S. Food and Drug Administration said Wednesday it has approved a form of gene therapy that is highly effective at fighting an aggressive form of leukemia in young patients with no other options. The treatment, to be marketed under the name Kymriah, is neither a pill nor an injection, but a...